Journée mondiale du diabète pour une meilleure prévention

Ce jeudi 14 novembre, c'est la journée mondiale du diabète. L'occasion de faire le point sur cette maladie qui touche plus de 350 millions de personnes dans le monde.

Ce jeudi 14 novembre célèbre la 22e Journée mondiale du diabète. Un événement qui entend sensibiliser l'opinion publique aux effets de cette maladie qui touche actuellement 371 millions de personnes dans le monde, selon l'Organisation mondiale de la santé (OMS) et plus de 600.000 personnes (dont 250.000 ignoraient en être atteintes) en Belgique. 

L'OMS estime que d'ici 2030, le diabète, qui se caractérise par une augmentation du taux de glucose dans le sang, sera la septième cause de décès dans le monde. Cette maladie est donc l'un des défis majeurs de santé et de développement du 21ème siècle.


Diabète: "protégeons notre futur"

Cette journée mondiale, créée en 1991 par l'OMS et la Fédération Internationale du Diabète (FID), a pour but de sensibiliser aux risques liés à cette maladie. Elle est célébrée par plus de 200 associations dans 160 pays dont l'Association Belge du Diabète (ABD). La campagne 2013 marque la dernière année de la campagne 2009 - 2013 consacrée à l'Education et à la Prévention du Diabète. 

Le slogan de cette année est "Diabète: protégeons notre futur" et s'articule autour de quatre messages-clés : 

1. Les pays les plus peuplés au monde : 1.Chine 2.Inde 3.DIABETE 4.Etats-Unis 5.Brésil
2. 1 personne sur 2 atteintes de diabète ne le sait pas : êtes-vous à risque ?
3. Diabète : attention aux complications
4. Les personnes atteintes de diabète sont comme vous et moi : non à la discrimination

Le diabète et ses complications sont en grande partie évitables, c'est pourquoi la FID que l'ABD militent pour la mise en place de stratégies efficaces de prévention et de contrôle de la maladie afin de préserver la santé des citoyens atteints de diabète ou à risque de devenir diabétique. 

Si le diabète de type 1 (insulino-dépendant), déclenché par des facteurs environnementaux, ne peut être prévenu, il est par contre possible d'éviter le diabète de type 2 (non insulino-dépendant) grâce à l'exercice d'une activité physique et en luttant contre l'obésité. L'éducation des patients a un rôle prépondérant, puisque ceux-ci doivent prendre en charge 95% de leurs soins.

Actuellement, plus de 350 millions de personnes sont atteintes de diabète de type 1 et la moitié des personnes atteintes ne sont pas conscientes de leur condition. 280 millions courent un risque élevé de développer la maladie. 

Même si les traitements ne permettent pas encore de guérir le diabète, les médications disponibles permettent toutefois de le contrôler correctement et d'en éviter la plupart des complications. Le traitement du diabète demande une participation active de la personne, laquelle est l'acteur principal de son traitement. Pour cela, il est essentiel que la personne diabétique reçoive une information ainsi qu'une éducation à la santé adaptée à ses besoins et encadrée par des professionnels de santé compétents.

Une journée de sensibilisation et d'action partout en Belgique 


De nombreuses manifestations auront lieu dans le cadre de cette journée parmi lesquelles des séances de sensibilisation, ainsi qu'une vaste campagne d'illuminations de monuments symboliques en bleu - la couleur de la Journée mondiale du Diabète. 

La campagne encourage également chacun à faire "Un pas" pour le diabète et à faire un don symbolique de pas lors de différentes activités. "Un pas" correspond à toute activité qui contribue à promouvoir la sensibilisation au diabète, à améliorer la vie des personnes atteintes de diabète, encourager un mode de vie sain ou réduire le risque individuel de développer la maladie. 

Différents événements seront également organisés dans les différents centres hospitaliers. C'est notamment le cas aujourd'hui au Centre hospitalier de Tubize-Nivelles, à la clinique Saint-Jean à Bruxelles ou encore à la clinique Saint-Luc à Bouge.

esterified estrogens and methyltestosterone, Estratest, Estratest HS

Notice: Solvay Pharmaceuticals, Inc. announced on March 10, 2009, that it would discontinue supplying the marketplace with ESTRATEST® (Esterified Estrogens and Methyltestosterone) Tablets and ESTRATEST® HS (Esterified Estrogens and Methyltestosterone) Tablets. Effective March 31, 2009, the company will no longer accept orders for new product from its customers.

GENERIC NAME: esterified estrogens and methyltestosterone

BRAND NAME: Estratest

DRUG CLASS AND MECHANISM: Esterified estrogens are a mixture of related estrogens. Estrogens, when taken alone or in combination with a progestin, have been shown to reduce the risk for hip fracture due toosteoporosis by 25% as well as the risk of heart attack (myocardial infarction) and stroke by 40-50%. Esterified estrogens are used for numerous medical situations. Estrogens cause growth and development of female sex organs and the maintain sex characteristics, including growth of underarm and pubic hair and shaping of body contours and skeleton. Estrogens also increase secretions from the cervix and growth of the inner lining of the uterus (endometrium). Estrogens reduce LDL-cholesterol ("bad"cholesterol) and increase HDL-cholesterol ("good" cholesterol) concentrations.

Testosterone is the major male sex hormone that is responsible for many male sexual characteristics, but women also produce small amounts of testosterone. Following menopause, a woman's production of testosterone decreases. When testosterone in the form of methyltestosterone is added to estrogens, there may be a further alleviation of the hot flashes seen aftermenopause, and there also may be an improvement in a woman's sexual function.

GENERIC AVAILABLE: no

PRESCRIPTION: yes

PREPARATIONS: Estratest tablets: esterified estrogens 0.625mg plus methyltestosterone 1.25mg; esterified estrogens 1.25mg plus methyltestosterone 2.5mg. Estratest HS is one-half the strength of Estratest.

STORAGE: Tablets should be stored at 36-86°F (20-30°C).

PRESCRIBED FOR: Estratest is prescribed for the treatment of the common symptoms associated with menopause (e.g., hot flashes, vaginal dryness).

DOSING: Estratest usually is prescribed as 1 or 2 tablets daily for 21 consecutive days followed by 7 days without medication.

DRUG INTERACTIONS: For drug interactions for esterified estrogens, please read the esterified estrogens article.

Methyltestosterone can increase the effects of warfarin (Coumadin), increasing the risk of bleeding. Taking methyltestosterone and imipramine(Tofranil) together has led to paranoia in a few patients. Methyltestosterone can increase blood concentrations of cyclosporine (Sandimmune; Neoral), which can increase the risk of kidney damage.

PREGNANCY: Both methyltestosterone and estrogens should not be used during pregnancy due to an increased risk of fetal abnormalities.

NURSING MOTHERS: Estrogens are secreted in milk and cause unpredictable effects in the infant. They should not be used during breast-feeding.

SIDE EFFECTS: For side effects, please read the esterified estrogensarticle.

Methyltestosterone can have masculinizing effects in women, the development of acne, growth of facial hair, enlargement of the clitoris, reduction in breast size, and deepening of the voice. If treatment is discontinued when these symptoms first appear, they usually diminish or disappear; however, prolonged treatment can cause irreversible masculinizing effects.

Reference: FDA Prescribing Information

أسرار صداع الشقيقة الاسباب العلاج النهائي الطبيعي الغذاء الميزان

كيف تفسر الصداع الذي يرافقه شعور بالتقيؤ؟ 

الجواب هذا على الأغلب هو صداع الشقيقة , وبنبذة بسيطة عن صداع الشقيقة نستطيع أن نقول أن صداع الشقيقة هو نوع من أنواع التحسس وذلك لارتباطه بما يعرف باسم البنية الحرضية التحسسية عند الإنسان , فقد وجد أن الناس الذين عندهم هذه البنية الحرضية التحسسية يصابون بخمسة أمراض هي الإكزيما والأرتكاريا وحمى القش ( حساسية الأنف والعيون ) والربو والشقيقة , وقد لاحظ العلماء أن واحدا من هذه الأمراض إذا ظهر عند فرد من العائلة فعلى الأغلب أن يكون هناك شخص آخر في نفس العائلة يعاني من مرض آخر في هذه المجموعة , يتميز صداع الشقيقة بحدوث انطلاق بعض المواد الكيميائية التي يعتقد أنها تنطلق بسبب التحسس الذي يشتد في فترة تحول الطقس مثل قدوم الربيع أو قدوم الخريف أو حتى تناول بعض الأطعمة أو الاضطراب الهرموني كما يحدث قبل الدورة الشهرية عند النساء , هذه المواد تسبب توسعا في الأوعية الدموية ثم تضيقا ثم توسعا , ولذلك فالشقيقة تعرف باسم الصداع الوعائي لأنه يحدث عملية التهابية في الأوعية الدموية , ويتميز ألمها بأن ينبض مثل النبض تماما وليس شرطا أن يكون صداع الشقيقة في نصف الرأس فقد يكون في الرأس كله , وقد يكون نصفيا بين اليمين واليسار أو الأعلى والأسفل أو الأمام والخلف من الرأس ولعل أهم ما يميز صداع الشقيقة ما يعرف باسم النسمة , فتضيق الأوعية في منطقة دماغية معينة سيؤثر على هذه المنطقة وعلى وظيفتها مما يجعل المريض قادرا على التنبؤ ببدء حدوث الصداع وذلك بسبب تاثر المنطقة الدماغية التي تبدأ بها هجمة تضيق الأوعية , حيث قد يشم رائحة غريبة إذا كان تضيق الأوعية في منطقة الشم , أو يسمع صوت طنين أو تشويش إذا كان التشنج في منطقة السمع أو يصاب بتشوش في الرؤية إذا كان تضيق الأوعية في منطقة البصر أو شعور غريب حسب المنطقة التي يتضيق فيها الوعاء , ومن أعراض الشقيقة المميزة وجود أعراض الإقياء المترافقة معها إذا عادة ما يكون الإقياء مخففا لهجمة صداع الشقيقة وبعض الناس التي تكون لديهم أعراض الشقيقة شديدة جدا يتعمدون الإقياء بوضع أصبعهم في حلقهم حتى يخفف ذلك عنهم , ونقول لهم كان الله في عونكم , ونستخدم بنجاح باهر ومذهل وبتوفيق من الله مجموعة الصداع عندنا والتي تغطي كل آلية من آليات صداع الشقيقة المعروفة وكل مادة كيميائية تنطلق تؤثر على الأوعية الدموية وتسبب تقبضها أو توسعها فنحن هنا نريد أن نصيب الداء كما أخبر رسول الله صلى الله عليه وسلم " فإذا أصيب دواء الداء برأ بإذن الله " رواه مسلم ومجموعتنا للتخلص من صداع الشقيقة تشمل زيت وخل إكليل الجبل والخزامى والزنجبيل والميرمية والبابونج شربا ودهنا , حيث يلاحظ المريض الذي يستخدم المنتجات أن الهجمات تصبح أقل عددا وأقصر مدة وأقل كثافة إلى أن نصل إلى مرحلة بعد 4 أو 5 شهور تختفي الهجمات نهائية , وقد لاحظنا أيضا أن استخدام خليط الزيوت لخلاصات الأعشاب السابقة , واستخدامه دهنا في منطقة الجبهة ومن ثم إلى كل الراس عند بداية الصداع , يؤدي إلى إحباط الهجمة وزوالها بشكل نهائي دون استخدام أدوية أو حقن مثل حقن الفولترين أو البروفين او غيرها ويمكن الحصول على منتجاتنا من موزعينا الموجودين في كافة أنحاء العالم بإذن الله

Surviving Mesothelioma Testimonials

"Surviving Mesothelioma and Other Cancers: A Patient's Guide" is written by mesothelioma survivor Paul Kraus. It is the best-selling mesothelioma book in the world. Here's a small sampling of some of the unsolicited testimonials we have received from patients and their loved ones.

"As a four-year pleural mesothelioma survivor, I have found Paul's book to be an inspiring and educational guide to dealing and living with this cancer. I have had his book for three years and have read it through several times, with many references to various chapters over those years. I have gained so much from it and I am reading it again. I believe many of the approaches he has used (many of which I have adopted in lifestyle changes) are responsible for my continued survival after four years. Paul and his book have given me hope that the disease will not defeat me, and he has provided the tools to help me heal. My most grateful thanks to Paul and Sue Kraus, and to Cancer Monthly...Cancer Monthly is another wonderful resource to such as myself and I am so grateful for the various services it provides. From the wide variety of support and information Cancer Monthly offers, it is obvious there are many dedicated, caring people on board. You are truly helping those of us cope with one of life's larger challenges. I thank profusely everyone who cares about us and is working hard on many different levels to improve life for cancer patients and survivors. My best wishes to Mr. and Mrs. Kraus for continued healing, and to Cancer Monthly as you continue in your mission on behalf of all of us."

Heartfelt Mesothelioma Testimonials

"A unique, inspirational book by a fellow sufferer and dedicated Author and Educator. Written from the heart and with understanding there are guidelines to help enhance your body's own immune system. Through knowledge we gain power! This gives us strength to strive to achieve our best possible outcome."

"My father was diagnosed with pleural mesothelioma in June. I gave him the book and it really gave him hope. Because the book is written by another mesothelioma patient it really made a difference for him. Thank you for sharing your inspirational story!"

"Thank you Paul for writing your wonderful book of hope. With all the awful stuff on the internet about this disease, your book is like a ray of sunshine. I also want to thank Cancer Monthly for sending the additional materials about treatments, doctors, clinical trials, and mesothelioma lawyers. It helped me make better decisions."

"Cancer Monthly has been a wonderful resource in our search for information on what is available and where to find the best possible answers. Now that I finished reading Paul Kraus' book I have a good understanding of what you are really all about. The world needs more people like you and I feel privileged for your time."

"Thanks for the information. It was also a pleasure speaking with you. I hope you realize what a special thing you are doing. You have a lot to be proud of…As I said earlier, it's funny my 31 years of experience in surgery mean nothing dealing with this now, but my conversation with you did. Thanks again."

"Please pass on our heartfelt thanks to the Kraus' for the time they gave to all! Thanks so much for all the hard work that went into this. I'm sure many, many folks benefited immensely from what was heard. What a service you have provided to all of us hungry for help! God bless you!"

"I feel so much more hopeful every time I hear about survivors and especially them doing so with immune boosting therapies and other non traditional methods. Thank You so very much!"

For Mesothelioma Staging PET/CT Tops PET/MRI

Standard PET/CT beats PET/MRI for diagnosing and staging pleural tumors such as mesothelioma. That is the conclusion reached by a team of radiology researchers in Zurich who evaluated  the two imaging modalities side-by-side for a variety of different cancers, including mesothelioma. 

Positron emission tomography is a nuclear imaging technique that produces 3D images of functional or metabolic processes in the body. Patients are given a radioactive tracer (usually FDG, a molecule similar to glucose) and the PET machine detects concentrations of the tracer in body tissues. Because FDG is an analog of glucose, it will concentrate where metabolic activity is highest, often in cancer cells. The combination of PET with computed tomography, an X-ray imaging study that produces tomographic images or ‘slices’ of specific areas, is the most common combination used to diagnose and stage malignant mesothelioma. 

Magnetic resonance imaging (MRI) is another type of nuclear imaging. It uses a powerful magnet to produce images of the nuclei of atoms in the body.  It can produce both 2D and 3D images without using ionizing radiation and is considered good at showing contrast between the different soft tissues in the body.

But when 63 patients with mesothelioma or another cancer underwent a single sequence of MRI using a technique called a body coil followed immediately by PET/CT, the standard imaging combination came out on top. The researchers measured the maximum diameters of the lesions shown on CT and MRI images. They then measured overall differences in the detectability and conspicuity [how obvious the lesion appeared] in PET/CT and PET/MRI and examined differences in detectability based on the location and type of lesion being examined.

Among the total of 126 PET-positive lesions, there was “no statistically significant superiority of PET/CT over PET/MRI or vice versa in terms of lesion conspicuity”. However, when the researchers looked specifically at lesions found in the lung area, such as mesothelioma, PET/CT was found to be significantly better than PET/MRI. They also found PET/CT to be better at detecting cancer in the lymph nodes, a key method by which mesothelioma and other cancers spread. 

Writing on their finding in Insight into Imaging, the Swiss doctors concluded that PET/MRI “does not match entirely the diagnostic accuracy of standard low-dose PET/CT” for mesothelioma and lung cancers. They suggest, however, that it might be used as a backup solution in some patients, as long as more time was spent to obtain the highest quality MRI images. 

Sources: 

Appenzeller, P, et al, “PET/CT versus body boil PET/MRI: how low can you go?”, may 15, 2013, Epub ahead of print. 

Breast cancer - Sex and Intimacy

Sex and Intimacy

Many women find that breast cancer diagnosis and treatment seriously disrupt their sexual lives. First there are the most obvious issues—the physical changes, exhaustion, nausea and pain from treatment, self-image, empty energy reserves, and the emotional chaos from the diagnosis itself. But there are also many other issues that women and their partners may not even know they'll have to face.

Yet retaining intimacy in your relationship both during and after your breast cancer ordeal is critical to your overall recovery. Andsingle women who want to become part of a relationship worry how breast cancer will affect their prospects, about how and when to tell those prospective lovers about their condition.

Adapted in part from Living Beyond Breast Cancer by Marisa Weiss, M.D. and Ellen Weiss

Federal breast cancer screening campaign

The federal government will launch a multimillion-dollar campaign to encourage older women to undergo breast cancer screening.

Health Minister Tanya Plibersek was in Sydney on Mother's Day to announce an extra $55.7 million in Tuesday's budget to expand the screening target group to include women aged 70 to 74.

Currently only women aged 50 to 69 get a mammogram reminder from BreastScreen Australia.

The new funding means another 70,000 women every year will get the letter.

The government hopes this will lead to the early detection and treatment of 600 extra breast cancer cases a year from 2016 onwards.

"Many people go without being reminded but I've got to say I'm one of those people who relies on the letter turning up in the mail for the other registers we have," Ms Plibersek told reporters on Sunday.

"This investment in expanding the target age range, picking up - we hope - an extra 600 cancers every year (when) they're more treatable, we hope that will save lives."

Cancer Australia CEO Helen Zorbas said the BreastScreen Australia program had already reduced breast cancer mortality by 25 per cent since its introduction.

"Breast cancer is the most common cancer in women in Australia and with the ageing of the population more and more women are being diagnosed every year," she said.

"The strongest risk factor for breast cancer is getting older. So this announcement of increasing the target age range for women who participate in breast cancer screening from 69 to 74 is really welcome."

Ms Plibersek also announced $10,000 in government funding for the National Breast Cancer Foundation at the Mother's Day Classic, a nationwide fun run and the foundation's biggest single fundraiser.

This year organisers say more than 130,000 people across the country are walking or running as part of the event, which is on track to beat the previous fundraising record of $4 million.

High-profile participants include Sarah and Lachlan Murdoch, Governor-General Quentin Bryce and celebrity pasty chef Adriano Zumbo.

Low-Dose Aspirin May Halt Breast Cancer

Research done in test tubes and in mice presented at a conference in Boston in the US at the weekend suggests taking low doses of aspirin on a regular basis may stop breast cancer from growing and spreading. However, cancer campaigners urge caution as the results are very early stage and have yet to be shown in patients.

The research team, from the Veterans Affairs Medical Center in Kansas City and the University of Kansas Medical Center, say tests on cancer cell lines and in mice show that aspirin not only significantly slows growth of cancer cells and shrinks tumors, but also stops tumor cells spreading to new sites.

Their study investigated the effect of aspirin on two types of cancer, including the so-called aggressive "triple-negative" breast cancer, which is immune to most treatments.

Triple-negative breast cancers are so-called because they lack receptors for estrogen, progesterone and Her2/neu.

The researchers presented their findings at the annual meeting of the American Society for Biochemistry and Molecular Biology. 

A meeting abstract of the study appears in the FASEB journal.

Aspirin's Effect on Cancer First Suggested 20 Years Ago

For over 20 years, since a study in Australia first suggested aspirin may have anti-cancer properties, researchers have been finding the headache drug may prevent and also treat all sorts of cancer. 

For example, there are reports that colon cancer survival improves with aspirin use, and thataspirin and other commonly used painkillers may also help guard against skin cancer. 

It has also has been shown to reduce the risk of squamous cell esophageal cancer andprostate cancer.

At first it was thought the effect only kicked in after ten years or so, but in 2012, three Lancetstudies of people in middle age taking low-dose aspirin suggested that the anti-cancer benefits may start after only three years.

Aspirin May Halt Cancer By Acting on Cancer Stem Cells

However, despite all this evidence, the underlying mechanism through which aspirin confers its anti-cancer benefits have been somewhat difficult to establish.

Now this latest study suggests that for breast cancer, it may be that aspirin interferes with the stem cells that are believed to fuel the growth and spread of tumors.

In a press statement, senior author Sushanta Banerjee, director of the cancer research unit and a professor at the University of Kansas Medical Center, says first-line chemotherapy does not destroy stem cells: eventually the tumor will start to grow again.

"If you don't target the stemness, it is known you will not get any effect," he adds, "It will relapse."

Banerjee and colleagues found that in the mouse model they used, cancer cells treated with aspirin formed no or only partial stem cells. 

And in lab tests, aspirin blocked the growth of two different breast cancer lines.

Aspirin Halted Triple-Negative Breast Cancer In Cell Lines

One of the cell lines the researchers used was of what is often called triple-negative breast cancer, which is a less common but much more difficult form of breast cancer to treat.

Banerjee, who is also a professor of medicine in the university's division of hematology and oncology, says he and his team are mainly interested in triple-negative breast cancer because the prognosis is very poor for patients who find themselves with this form of the disease.

The reaction from cancer campaigners has been welcoming but cautious.

According to The Independent, Eluned Hughes, of the UK charity Breakthrough Breast Cancer, urges caution over the "incredibly early stage research" which is yet to be replicated in human patients. But she says they will be watching its progress closely, "it could be promising for the future", and they hope to continue to see new options for patients.

Aspirin May Also Boost Treatments for Hormone-Positive Breast Cancers

The researchers say aspirin may also improve the effectiveness of current treatments for hormone-receptor-positive breast cancers. In their study, they found aspirin boosted the effect of tamoxifen, which is used to treat hormone-positive breast cancers.

Aspirin treats many different conditions. Banerjee says its ability to target several metabolic pathways could be why it is effective against cancer:

"Cancer is not a single-gene disease," explains Banerjee, "Multiple genes are involved."

Many people take a daily low dose of aspirin to lower their risk of a further heart attack orstroke, or if they have a high risk of either.

But taking aspirin is not without risks; for instance daily aspirin use can increase the risk of gastrointestinal bleeding.

Researchers are continuing to investigate whether the advantages outweigh the potential disadvantages.

In 2012 the National Cancer Institute invited scientists to explore how drugs like aspirin, primarily intended for other purposes, might also reduce the risk of developing cancer or extend survival for those who have it.

Banerjee says his lab will be applying for one of these grants.

Omega-3 Fatty Acids Slow Triple-Negative Breast Cancer Cell Proliferation

Omega-3 fatty acids, as well as their metabolite products, stop or slow the proliferation of triple-negative breast cancer cells better than cells from luminal types of cancer, researchers from Fox Chase Cancer Center reported at the AACR Annual Meeting 2013.

The scientists explained that omega-3 fatty acids work against all cancerous cell types, but were seen to be much more effective against the triple-negative cell lines. Proliferation in those types of cells was reduced by as much as 90%.

Sardines, tuna, trout, salmon (oily fish), flax and hemp are examples of foods rich in omega-3s. Several studies have already demonstrated their benefits in undermining the critical mechanisms in cancer cells, specifically those responsible for apoptosis (programmed cell death) and proliferation. Thomas J. Pogash explained that the team's finding underscores the vital role that compounds commonly found in our foods play in fighting off cancer.

Pogash said:

"Diet can play a critical role in breast cancer prevention. When you compare a western diet to a mediterranean diet, which has more omega-3s, you see less cancer in the mediterranean diet. They eat much more fish."

Breast cancers are not all the same; they differ at molecular levels. That is why patients do not all respond the same to treatments.

Experts categorize breast cancer tumors into four distinct groups:

• Luminal A
• Luminal B
In Luminal A and B, the luminal cells that line the milk ducts have estrogen and progesterone receptors. These patients generally have better prognoses.


• Tumors that test positive for the HER3 receptor
• Triple-negative tumors - these lack receptors for estrogen, progesterone and HER2/neu (a protein). For patients with this type of breast cancer, treatments with trastuzumab, which disrupts the HER2 receptor, and tamoxifen, which targets the estrogen receptor, do not work.

Dr. Jose Russo wrote that there are no currently available targeted therapies for women with triple-negative breast cancer. Standard care for early stage disease involves combination chemotherapies.

Russo said:

"This type of cancer, which is found more frequently in Latina and African-American women, is highly aggressive and has a low survival rate. There is not any specific treatment for it."

When a cancerous cell digests omega-3 fatty acids, they are broken down into metabolites (smaller molecules). The team wanted to determine what the effect might be of large omega-3 parent molecules, as well as their metabolic derivatives, on three luminal cell lines and seven basal-type triple-negative cell lines.

The scientists found that omega-3 and its metabolites undermine proliferation in all cell lines. However, they were dramatically more effective in inhibiting proliferation in the triple-negative cell lines.

They also found that the omega-3 metabolites reduced motility by 20% to 60% in triple-negative basal cell lines.

This study is being funded by the Komen Foundation and is part of a consortium between Fox Chase Cancer Center and Pennsylvania State University. The lead researchers are Dr. Jose Russo (at Fox Chase) and Dr. Andrea Manni (at Penn State).

Russo and team are currently working on the role of epigenetic events in the mechanism of cell transformation. They are also involved in another project which is looking at the potential action of peptides of the hormone hCG (human chorionic gonadotropin) on breast cancer prevention.

Many studies on omega-3 fatty acids

Over the last fifteen years, there have been many studies on the benefits of consuming omega-3 fatty acids. Not all of them have had positive findings. Below are some of them:

• Skin cancer - scientists form the University of Manchester, England, reported in theAmerican Journal of Clinical Nutrition (February 2013 issue) that consuming omega-3 fish oils can help prevent skin cancer.


• Memory - healthy young adults who increase their consumption of omega-3s can have better working memory, a team from the University of Pittsburgh reported in the journalPLoS ONE (October 2012 issue).


• No benefit - a team from the University Hospital of Ioannina, Ioannina, Greece, reviewed twenty studies involving 70,000 participants. They found no statistically significant evidence that omega-3 fatty acid supplementation helped reduce stroke, heart attack or premature death. They reported their findings in JAMA (September 2012 issue). The authors stressed that they did not rule out the possibility that some groups may benefit, and called for further studies to be carried out.


• Retinitis pigmentosa progression - experts from the Harvard Medical School and the Massachusetts Eye and Ear Infirmary, Boston, reported in Archives of Ophthalmology(February 2012 issue) that diets rich in omega-3 fatty acids help slow down the progression of retinitis pigmentosa.

What Is Breast Cancer? What Causes Breast Cancer?

Breast cancer is a kind of cancer that develops from breast cells. Breast cancer usually starts off in the inner lining of milk ducts or the lobules that supply them with milk. A malignant tumor can spread to other parts of the body. A breast cancer that started off in the lobules is known as lobular carcinoma, while one that developed from the ducts is called ductal carcinoma.

The vast majority of breast cancer cases occur in females. This article focuses on breast cancer in women. To read about breast cancer in men (male breast cancer)click here.

Breast cancer is the most common invasive cancer in females worldwide. It accounts for 16% of all female cancers and 22.9% of invasive cancers in women. 18.2% of all cancer deaths worldwide, including both males and females, are from breast cancer.

Breast cancer rates are much higher in developed nations compared to developing ones. There are several reasons for this, with possibly life-expectancy being one of the key factors - breast cancer is more common in elderly women; women in the richest countries live much longer than those in the poorest nations. The different lifestyles and eating habits of females in rich and poor countries are also contributory factors, experts believe.

The anatomy of a female breast

1. Chest wall. 2. Pectoralis muscles. 3. Lobules (glands that make milk). 4. Nipple surface. 5. Areola. 6. Lactiferous duct tube that carries milk to the nipple. 7. Fatty tissue. 8. Skin.


A mature human female's breast consists of fat, connective tissue and thousands of lobules - tiny glands which produce milk. The milk of a breastfeeding mother goes through tiny ducts (tubes) and is delivered through the nipple.

The breast, like any other part of the body, consists of billions of microscopic cells. These cells multiply in an orderly fashion - new cells are made to replace the ones that died. In cancer, the cells multiply uncontrollably, and there are too many cells, progressively more and more than there should be.

Cancer that begins in the lactiferous duct (milk duct), known as ductal carcinoma, is the most common type. Cancer that begins in the lobules, known as lobular carcinoma, is much less common.

What is the difference between invasive and non-invasive breast cancer?

Invasive breast cancer - the cancer cells break out from inside the lobules or ducts and invade nearby tissue. With this type of cancer, the abnormal cells can reach the lymph nodes, and eventually make their way to other organs (metastasis), such as the bones, liver or lungs. The abnormal (cancer) cells can travel through the bloodstream or the lymphatic system to other parts of the body; either early on in the disease, or later.

Non-invasive breast cancer - this is when the cancer is still inside its place of origin and has not broken out. Lobular carcinoma in situ is when the cancer is still inside the lobules, while ductal carcinoma in situ is when they are still inside the milk ducts. "In situ" means "in its original place". Sometimes, this type of breast cancer is called "pre-cancerous"; this means that although the abnormal cells have not spread outside their place of origin, they can eventually develop into invasive breast cancer.

What are the signs and symptoms of breast cancer?

A symptom is only felt by the patient, and is described to the doctor or nurse, such as aheadache or pain. A sign is something the patient and others can detect, for example, a rash or swelling.

The first symptoms of breast cancer are usually an area of thickened tissue in the woman's breast, or a lump. The majority of lumps are not cancerous; however, women should get them checked by a health care professional.

Some of the possible early signs of breast cancer

According to the National Health Service, UK, women who detect any of the following signs or symptoms should tell their doctor:

• A lump in a breast
• A pain in the armpits or breast that does not seem to be related to the woman's menstrual period
• Pitting or redness of the skin of the breast; like the skin of an orange
• A rash around (or on) one of the nipples
• A swelling (lump) in one of the armpits
• An area of thickened tissue in a breast
• One of the nipples has a discharge; sometimes it may contain blood
• The nipple changes in appearance; it may become sunken or inverted
• The size or the shape of the breast changes
• The nipple-skin or breast-skin may have started to peel, scale or flake

What are the causes of breast cancer?

Experts are not sure what causes breast cancer. It is hard to say why one person develops the disease while another does not. We know that some risk factors can impact on a woman's likelihood of developing breast cancer.

• Getting older - the older a woman gets, the higher is her risk of developing breast cancer; age is a risk factor. Over 80% of all female breast cancers occur among women aged 50+ years (after the menopause).


• Genetics - women who have a close relative who has/had breast or ovarian cancer are more likely to develop breast cancer. If two close family members develop the disease, it does not necessarily mean they shared the genes that make them more vulnerable, because breast cancer is a relatively common cancer.
  
  The majority of breast cancers are not hereditary.
  
  Women who carry the BRCA1 and BRCA2 genes have a considerably higher risk of developing breast and/or ovarian cancer. These genes can be inherited. TP53, another gene, is also linked to greater breast cancer risk.


• A history of breast cancer - women who have had breast cancer, even non-invasive cancer, are more likely to develop the disease again, compared to women who have no history of the disease.


• Having had certain types of breast lumps - women who have had some types of benign (non-cancerous) breast lumps are more likely to develop cancer later on. Examples include atypical ductal hyperplasia or lobular carcinoma in situ.


• Dense breast tissue - women with more dense breast tissue have a greater chance of developing breast cancer.


• Estrogen exposure - women who started having periods earlier or entered menopause later than usual have a higher risk of developing breast cancer. This is because their bodies have been exposed to estrogen for longer. Estrogen exposure begins when periods start, and drops dramatically during the menopause.


• Obesity - post-menopausal obese and overweight women may have a higher risk of developing breast cancer. Experts say that there are higher levels of estrogen in obese menopausal women, which may be the cause of the higher risk.


• Height - taller-than-average women have a slightly greater likelihood of developing breast cancer than shorter-than-average women. Experts are not sure why.


• Alcohol consumption - the more alcohol a woman regularly drinks, the higher her risk of developing breast cancer is.


• Radiation exposure - undergoing X-rays and CT scans may raise a woman's risk of developing breast cancer slightly. Scientists at the Memorial Sloan-Kettering Cancer Center found that women who had been treated with radiation to the chest for a childhood cancer have a higher risk of developing breast cancer. (Link to article)


• HRT (hormone replacement therapy) - both forms, combined and estrogen-only HRTtherapies may increase a woman's risk of developing breast cancer slightly. Combined HRT causes a higher risk.


• Certain jobs - French researchers found that women who worked at night prior to a first pregnancy had a higher risk of eventually developing breast cancer. (Link to article)
  
  Canadian researchers found that certain jobs, especially those that bring the human body into contact with possible carcinogens and endocrine disruptors are linked to a higher risk of developing breast cancer. Examples include bar/gambling, automotive plastics manufacturing, metal-working, food canning and agriculture. They reported their findings in the November 2012 issue of Environmental Health.


• Cosmetic implants may undermine breast cancer survival - women who have cosmetic breast implants and develop breast cancer may have a higher risk of dying prematurely form the disease compared to other females, researchers from Canada reported in the BMJ (British Medical Journal) (May 2013 issue).
  
  The team looked at twelve peer-reviewed articles on observational studies which had been carried out in Europe, the USA and Canada.
  
  Experts had long-wondered whether cosmetic breast implants might make it harder to spot malignancy at an early stage, because they produce shadows on mammograms.
  
  In this latest study, the authors found that a woman with a cosmetic breast implant has a 25% higher risk of being diagnosed with breast cancer when the disease has already advanced, compared to those with no implants.
  
  Women with cosmetic breast implants who are diagnosed with breast cancer have a 38% higher risk of death from the disease, compared to other patients diagnosed with the same disease who have no implants, the researchers wrote.
  
  After warning that there were some limitations in the twelve studies they looked at, the authors concluded "Further investigations are warranted into the long term effects of cosmetic breast implants on the detection and prognosis of breast cancer, adjusting for potential confounders."

Diagnosing breast cancer

Women are usually diagnosed with breast cancer after a routine breast cancer screening, or after detecting certain signs and symptoms and seeing their doctor about them.

If a woman detects any of the breast cancer signs and symptoms described above, she should speak to her doctor immediately. The doctor, often a primary care physician (general practitioner, GP) initially, will carry out a physical exam, and then refer the patient to a specialist if he/she thinks further assessment is needed.

Below are examples of diagnostic tests and procedures for breast cancer:

• Breast exam - the physician will check both the patient's breasts, looking out for lumps and other possible abnormalities, such as inverted nipples, nipple discharge, or change in breast shape. The patient will be asked to sit/stand with her arms in different positions, such as above her head and by her sides.


• X-ray (mammogram) - commonly used for breast cancer screening. If anything unusual is found, the doctor may order a diagnostic mammogram.
  
  Breast cancer screening has become a controversial subject over the last few years. Experts, professional bodies, and patient groups cannot currently agree on when mammography screening should start and how often it should occur. Some say routine screening should start when the woman is 40 years old, others insist on 50 as the best age, and a few believe that only high-risk groups should have routine screening.
  
  In July, 2012, The American Medical Association said that women should be eligible for screening mammography from the age of 40, and it should be covered by insurance.
  
  In a Special Report in The Lancet (October 30th, 2012 issue), a panel of experts explained that breast cancer screening does reduce the risk of death from the disease. However, they added that it also creates more cases of false-positive results, where women end up having unnecessary biopsies and harmless tumors are surgically removed.
  
  Another study, carried out by scientists at the The Dartmouth Institute for Healthy Policy & Clinical Practice in Lebanon, N.H., and reported in the New England Journal of Medicine(November 2012 issue), found that mammograms do not reduce breast cancer death rates.
  
  A team from the University of Copenhagen reported that women who have false-positive mammogram outcomes may suffer long-lasting stress and anxiety, in some cases this can last up to three years. They published their findings in Annals of Family Medicine (March 2013 issue).
  
  Researchers from the Barbara Ann Karmanos Cancer Institute in Detroit, Michigan, found that breast cancer mortality was higher among older women whose time-lapses between their last mammogram and their breast cancer diagnosis were longer. They presented their findings at the American Association for Cancer Research (AACR) Annual Meeting 2013.
  
  Team leader, Michael S. Simon, M.D., M.P.H., said "We found that for women age 75 and older, a longer time interval between the last mammogram and the date of breast cancer diagnosis was associated with a greater chance for dying from breast cancer."


• 2D combined with 3D mammograms - 3D mammograms, when used in collaboration with regular 2D mammograms were found to reduce the incidence of false positives, researchers from the University of Sydney's School of Public Health, Australia, reported inThe Lancet Oncology.
  
  The researchers screened 7,292 adult females, average age 58 years. Their initial screening was done using 2D mammograms, and then they underwent a combination of 2D and 3D mammograms.
  
  Professor Nehmat Houssami and team found 59 cancers in 57 patients. 66% of the cancers were detected in both 2D and combined 2D/3D screenings. However, 33% of them were only detected using the 2D plus 3D combination.
  
  The team also found that 2D plus 3D combination screenings were linked to a much lower number of false positives. When using just 2D screenings there were 141 false positives, compared to 73 using the 2D plus 3D combination.
  
  Prof. Houssami said "Although controversial, mammography screening is the only population-level early detection strategy that has been shown to reduce breast cancer mortality in randomized trials. Irrespective of which side of the mammography screening debate one supports, efforts should be made to investigate methods that enhance the quality of, and hence potential benefit from, mammography screening.
  
  We have shown that integrated 2D and 3D mammography in population breast-cancer screening increases detection of breast cancer and can reduce false-positive recalls depending on the recall strategy. Our results do not warrant an immediate change to breast-screening practice, instead, they show the urgent need for randomised controlled trials of integrated 2D and 3D versus 2D mammography."


• Beast ultrasound - this type of scan may help doctors decide whether a lump or abnormality is a solid mass or a fluid-filled cyst.


• Biopsy - a sample of tissue from an apparent abnormality, such as a lump, is surgically removed and sent to the lab for analysis. It the cells are found to be cancerous, the lab will also determine what type of breast cancer it is, and the grade of cancer (aggressiveness). Scientists from the Technical University of Munich found that for an accurate diagnosis, multiple tumor sites need to be taken. (Link to article)


• Breast MRI (magnetic resonance imaging) scan - a dye is injected into the patient. This type of scan helps the doctor determine the extent of the cancer. Researchers from the University of California in San Francisco found that MRI provides a useful indication of a breast tumor's response to pre-surgical chemotherapy much earlier than possible through clinical examination. (Link to article)

Staging describes the extent of the cancer in the patient's body and is based on whether it is invasive or non-invasive, how large the tumor is, whether lymph nodes are involved and how many, and whether it has metastasized (spread to other parts of the body).

A cancer's stage is a crucial factor in deciding what treatment options to recommend, and in determining the patient's prognosis.

Staging is done after cancer is diagnosed. To do the staging, the doctor may order several different tests, including blood tests, a mammogram, a chest X-ray, a bone scan, a CT scan, or a PET scan.

Ads by Google

Vegetables And Cancer - Learn How You Can Fight Cancer With Vegetable Juicing. Watch Now! - www.FoodMatters.tv/VegesAndJuicing

Radiation - Siemens radiology technologies help detect diseases earlier. -siemens.co.za/Radiation

Blood Clot Treatments - A resource for physicians and patients about thrombosis! - www.Thrombosisadviser.com

What are the treatment options for breast cancer?

A multidisciplinary team will be involved in a breast cancer patient's treatment. The team may consists of an oncologist, radiologist, specialist cancer surgeon, specialist nurse, pathologist, radiologist, radiographer, and reconstructive surgeon. Sometimes the team may also include an occupational therapist, psychologist, dietitian, and physical therapist.

The team will take into account several factors when deciding on the best treatment for the patient, including:

• The type of breast cancer


• The stage and grade of the breast cancer - how large the tumor is, whether or not it has spread, and if so how far


• Whether or not the cancer cells are sensitive to hormones


• The patient's overall health


• The age of the patient (has she been through the menopause?)


• The patient's own preferences

The main breast cancer treatment options may include:

• Radiation therapy (radiotherapy)
• Surgery
• Biological therapy (targeted drug therapy)
• Hormone therapy
• Chemotherapy

Surgery

• Lumpectomy - surgically removing the tumor and a small margin of healthy tissue around it. In breast cancer, this is often called breast-sparing surgery. This type of surgery may be recommended if the tumor is small and the surgeon believes it will be easy to separate from the tissue around it. British researchers reported that about one fifth of breast cancer patients who choose breast-conserving surgery instead of mastectomy eventually need a reoperation. (Link to article)


• Mastectomy - surgically removing the breast. Simple mastectomy involves removing the lobules, ducts, fatty tissue, nipple, areola, and some skin. Radical mastectomy means also removing muscle of the chest wall and the lymph nodes in the armpit.


• Sentinel node biopsy - one lymph node is surgically removed. If the breast cancer has reached a lymph node it can spread further through the lymphatic system into other parts of the body.


• Axillary lymph node dissection - if the sentinel node was found to have cancer cells, the surgeon may recommend removing several nymph nodes in the armpit.


• Breast reconstruction surgery - a series of surgical procedures aimed at recreating a breast so that it looks as much as possible like the other breast. This procedure may be carried out at the same time as a mastectomy. The surgeon may use a breast implant, or tissue from another part of the patient's body.

Radiation therapy (radiotherapy)

Controlled doses of radiation are targeted at the tumor to destroy the cancer cells. Usually, radiotherapy is used after surgery, as well as chemotherapy to kill off any cancer cells that may still be around. Typically, radiation therapy occurs about one month after surgery or chemotherapy. Each session lasts a few minutes; the patient may require three to five sessions per week for three to six weeks.

The type of breast cancer the woman has will decide what type of radiation therapy she may have to undergo. In some cases, radiotherapy is not needed.

Radiation therapy types include:

• Breast radiation therapy - after a lumpectomy, radiation is administered to the remaining breast tissue


• Chest wall radiation therapy - this is applied after a mastectomy


• Breast boost - a high-dose of radiation therapy is applied to where the tumor was surgically removed. The appearance of the breast may be altered, especially if the patient's breasts are large.


• Lymph nodes radiation therapy - the radiation is aimed at the axilla (armpit) and surrounding area to destroy cancer cells that have reached the lymph nodes


• Breast brachytherapy - scientists at UC San Diego Moores Cancer Center revealed that patients with early-stage breast cancer in the milk ducts which has not spread, seem to benefit from undergoing breast brachytherapy with a strut-based applicator. This 5-day treatment is given to patients after they have undergone lumpectomy surgery. The researchers found that women who received strut-based breast brachytherapy had lower recurrence rates, as well as fewer and less severe side effects. (Link to article)

Side effects of radiation therapy may include fatigue, lymphedema, darkening of the breast skin, and irritation of the breast skin.

Chemotherapy

Medications are used to kill the cancer cells - these are called cytotoxic drugs. The oncologist may recommend chemotherapy if there is a high risk of cancer recurrence, or the cancer spreading elsewhere in the body. This is called adjuvant chemotherapy.

If the tumors are large, chemotherapy may be administered before surgery. The aim is to shrink the tumor, making its removal easier. This is called neo-adjuvant chemotherapy. 

Chemotherapy may also be administered if the cancer has metastasized - spread to other parts of the body. Chemotherapy is also useful in reducing some of the symptoms caused by cancer.

Chemotherapy may help stop estrogen production. Estrogen can encourage the growth of some breast cancers.

Side effects of chemotherapy may include nausea, vomiting, loss of appetite, fatigue, sore mouth, hair loss, and a slightly higher susceptibility to infections. Many of these side effects can be controlled with medications the doctor can prescribe. Women over 40 may enter early menopause.

Protecting female fertility - Scientists have designed a way of aggressively attacking cancer with an arsenic-based chemo medication, which is much gentler on the ovaries. The researchers, from Northwestern University Feinberg School of Medicine in Chicago, believe their novel method will help protect the fertility of female patients undergoing cancer treatment.

The scientists say they also developed a way of rapidly testing existing chemotherapy drugs for their effect on ovarian function, so that doctors and patients can make decisions regarding treatment that minimize damage to ovaries.

They reported their findings in the journal PLOS ONE (March 2013 issue). The authors claim that the new nanoparticle chemo medication they designed is the first cancer drug to be tested during development for its impact on fertility using the new rapid toxicity test.

Although more cancer patients are surviving today thanks to the advances in cancer therapies, a significant number of female patients still face fertility loss after undergoing traditional chemotherapy.

Co-principal study investigator Teresa Woodruff, said "Our overall goal is to create smart drugs that kill the cancer but don't cause sterility in young women."

Hormone therapy (hormone blocking therapy)

Used for breast cancers that are sensitive to hormones. These types of cancer are often referred to as ER positive (estrogen receptor positive) and PR positive (progesterone receptor positive) cancers. The aim is to prevent cancer recurrence. Hormone blocking therapy is usually used after surgery, but may sometimes be used beforehand to shrink the tumor.

If for health reasons, the patient cannot undergo surgery, chemotherapy or radiotherapy, hormone therapy may be the only treatment she receives.

Hormone therapy will have no effect on cancers that are not sensitive to hormones.

Hormone therapy usually lasts up to five years after surgery.

The following hormone therapy medications may be used:

• Tamoxifen - prevents estrogen from binding to ER-positive cancer cells. Side effects may include changes in periods, hot flashes, weight gain, headaches, nausea, vomiting, fatigue, and aching joints.
  
  A biomarker in breast cancer patients who do not respond, or who have become resistant to Tamoxifen has been discovered by researchers at the University of Manchester, England. They say that their discovery will help doctors decide which patients are suitable or not for adjuvant (complementary) hormone therapy with Tamoxifen.


• Aromatase inhibitors - this type of medication may be offered to women who have been through the menopause. It blocks aromatase. Aromatase helps estrogen production after the menopause. Before the menopause, a woman's ovaries produce estrogen. Examples of aromatase inhibitors include letrozole, exemestane, and anastrozole. Side effects may include nausea, vomiting, fatigue, skin rashes, headaches, bone pain, aching joints, loss of libido, sweats, and hot flashes.

Ovarian ablation or suppression - pre-menopausal women produce estrogen in their ovaries. Ovarian ablation or suppression stop the ovaries from producing estrogen. Ablation is done either through surgery or radiation therapy - the woman's ovaries will never work again, and she will enter the menopause early.

A luteinising hormone-releasing hormone agonist (LHRHa) drug called Goserelin will suppress the ovaries. The patient's periods will stop during treatment, but will start again when she stops taking Goserelin. Women of menopausal age (about 50 years) will probably never start having periods again. Side effects may include mood changes, sleeping problems, sweats, and hot flashes.

Biological treatment (targeted drugs)

• Trastuzumab (Herceptin) - this monoclonal antibody targets and destroys cancer cells that are HER2-positive. Some breast cancer cells produce large amounts of HER2 (growth factor receptor 2); Herceptin targets this protein. Possible side effects may include skin rashes, headaches, and/or heart damage.


• Lapatinib (Tykerb) - this drug targets the HER2 protein. It is also used for the treatment of advanced metastatic breast cancer. Tykerb is used on patients who did not respond well to Herceptin. Side effects include painful hands, painful feet, skin rashes, mouth sores, extreme tiredness, diarrhea, vomiting, and nausea.


• Bevacizumab (Avastin) - stops the cancer cells from attracting new blood vessels, effectively causing the tumor to be starved of nutrients and oxygen. Side effects may include congestive heart failure, hypertension (high blood pressure), kidney damage, heart damage, blood clots, headaches, mouth sores. Although not approved by the FDA for this use, doctors may prescribe it "off-label". Using this drug for breast cancer is controversial. The FDA in 2011 said that Avastin is neither effective nor safe for breast cancer. (Link to article)
  
  Swiss researchers found that Avastin offers only a modest benefit regarding disease progression in women with advanced stage breast cancer. They added that it has no impact on survival. (Link to article)


• Low dose aspirin
  
  Research carried out on laboratory mice and test tubes suggests that regular low-dose aspirin may halt the growth and spread of breast cancer.
  
  Scientists from the Veterans Affairs Medical Center in Kansas City and the University of Kansas Medical Center explained that their tests on cancer lines and in mice showed thataspirin not only slowed the growth of cancer cells and shrank tumors considerably, but also stopped metastasis (cancer spreading to new sites).
  
  Their research involved assessing aspirin's effects on two types of cancer, including the aggressive "triple-negative" breast cancer which is resistant to most current treatments.
  
  Cancer campaigners cautioned that although the current results show great promise, this research is at a very early stage and has yet to be shown to be effective on humans.

Exercise and cancer survival rates - an report published in the Journal of the National Cancer Institute explained that physical activity is associated with lower rates of breast andcolon cancer deaths. (Link to article)

Preventing breast cancer

Some lifestyle changes can help significantly reduce a woman's risk of developing breast cancer.

• Alcohol consumption - women who drink in moderation, or do not drink alcohol at all, are less likely to develop breast cancer compared to those who drink large amounts regularly. Moderation means no more than one alcoholic drink per day.


• Physical exercise - exercising five days a week has been shown to reduce a woman's risk of developing breast cancer. Researchers from the University of North Carolina Gillings School of Global Public Health in Chapel Hill reported that physical activity - either mild or intense and before or after menopause - can lower breast cancer risk, but considerable weight gain may negate these benefits. (Link to article)


• Diet - some experts say that women who follow a healthy, well-balanced diet may reduce their risk of developing breast cancer.


• Postmenopausal hormone therapy - limiting hormone therapy may help reduce the risk of developing breast cancer. It is important for the patient to discuss the pros and cons thoroughly with her doctor.


• Bodyweight - women who have a healthy bodyweight have a considerably lower chance of developing breast cancer compared to obese and overweight females.


• Women at high risk of breast cancer - the doctor may recommend estrogen-blocking drugs, including tamoxifen and raloxifene. Tamoxifen may raise the risk of uterine cancer. Preventive surgery is a possible option for women at very high risk.


• Breast cancer screening - patients should discuss with their doctor when to start breast cancer screening exams and tests.


• Breastfeeding - women who breastfeed run a lower risk of developing breast cancer compared to other women.

Survivors of breast cancer and diabetes risk

Postmenopausal women who survived breast cancer are more likely to develop diabetes, compared to other women of their age who did not have breast cancer, researchers from the Women's College Hospital, Women's College Research Institute, Toronto, reported in the journal Diabetologia.

The authors added that breast cancer survivors who had undergone chemotherapy were especially at risk of developing diabetes.

Over the last few years, scientists have become increasingly aware of a link between cancer and diabetes. The association works the other way round too - women with diabetes are 20% more likely to develop breast cancer after the menopause compared to their counterparts who are not diabetic.

More women are surviving breast cancer, experts say, making it much more important to understand what the long-term outcomes for survivors are as they grow older.